First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Inclusion Criteria: * Advanced-stage solid tumor (metastatic or locally advanced and unresectable) with histologically confirmed diagnosis of CRC, NSCLC, GC, RCC, or HCC * Measurable lesion(s) according to RECIST 1.1 criteria * Performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale. * Ability to swallow capsules * Received last chemotherapy, biologic, or investigational therapy at least 4 weeks prior to first dosing of study treatment * Has received or is intolerant to all standard of care treatment options with known clinical benefit * Life expectancy of more than 3 months * Adequate hematological, hepatic and renal function * For women of childbearing potential, a negative serum pregnancy test performed within 7 days prior to start of treatment Exclusion Criteria: * Received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry * Major surgery within the last 28 days prior to the first dose of investigational drug * Prior radiation therapy within 14 days prior to study Cycle 1 Day 1 and/or persistence of radiation-related adverse effects. * Concurrent treatment with any anticancer agent * Currently taking either strong CYP inhibitors or inducers * Known brain metastases, uncontrolled seizure disorder, or active neurologic disease * Significant cardiovascular impairment * Pregnant or nursing * Known HIV infection, active hepatitis C and/or hepatitis B infection * Known bleeding disorder or coagulopathy * Active drug or alcohol abuse or history of alcohol or drug abuse during the last two years. * Diagnosis of osteoporosis at the time of the screening * Any history of retinal pathology including diabetic retinopathy, macular degeneration, or other retinal degenerative disease